KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

LANOXIN 0.125 MG TABLETS

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

0.125 MG

 

GENERIC NAME:

DIGOXIN

 

MANUFACTURER:

GLAXO WELLCOME

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

C

 

INDICATIONS:

Toxicity, digoxin

 

SIDE EFFECTS:

hyperkalemia

hypokalemia

impaired cognition

impotence

libido decrease

maculopapular rash

nausea/vomiting

paresthesias

photophobia

PR prolongation

premature ventricular contractions (PVCs)

pruritus

psychosis

sinus bradycardia

sinus tachycardia

ST-T wave changes

Stevens-Johnson syndrome

syncope

thrombocytopenia

ventricular tachycardia

visual impairment

weakness

xanthopsia

abdominal pain

anorexia

anxiety

atrial fibrillation

atrial tachycardia

AV block

blurred vision

confusion

constipation

delirium

depression

diarrhea

dizziness

drowsiness

erythema

fatigue

gynecomastia

hallucinations

headache

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

acute myocardial infarction

Adams-Stokes syndrome

AV block

bradycardia

breast-feeding

cardiomyopathy

carotid sinus hypersensitivity

constrictive pericarditis

cor pulmonale

elderly

electrolyte imbalance

hepatic disease

hypercalcemia

hyperkalemia

hypertension

hyperthyroidism

hypocalcemia

hypokalemia

hypomagnesemia

hypothyroidism

hypoxemia

idiopathic hypertrophic subaortic stenosis

myxedema

pregnancy

pulmonary disease

renal disease

renal failure

renal impairment

sick sinus syndrome

ventricular arrhythmias

ventricular tachycardia

 

ADULT DOSE:

Congestive heart failure-Digitalization- Rapid digitalization is achieved by administering a loading dose based upon projected peak digoxin body stores (e.g., body stores of 8 to 12 mcg per kg of body weight in patients with heart failure and normal sinus rhythm; 6 to 10 mcg per kg of body weight for patients with renal insufficiency) : Oral, roughly one half the total loading dose given as the first dose, with the remaining portion divided and administered every six to eight hours (e.g., 500 to 750 mcg [0.5 to 0.75 mg] initially, followed by 125 to 375 mcg [0.125 to 0.375 mg] administered every six to eight hours) until an appropriate clinical response is achieved . Before each additional dose is given, the patient's clinical response should be assessed carefully . If the patient's clinical response requires a change from the calculated loading dose of digoxin, calculation of the maintenance dose should be based upon the amount actually given . For a 70-kg patient to achieve 8 to 12 mcg per kg of body weight peak body stores, the usual amount administered is 750 to 1250 mcg (0.75 to 1.25 mg) . Slow digitalization is achieved by beginning an appropriate maintenance dose (allowing digoxin body stores to accumulate slowly) and will be achieved in approximately five half-lives . Depending upon the patient's renal function, digitalization by this method will take between one and three weeks . Maintenance- Digoxin maintenance doses for estimated peak body stores of 10 mcg per kg of body weight generally have ranged from 62.5 to 500 mcg (0.0625 to 0.5 mg), administered orally as one or two doses per day, the dosage titrated according to the patient's age, lean body weight, and renal function . In patients digitalized with a loading dose, the subsequent maintenance dose can be calculated as a percentage of the loading dose . Doses may be increased every two weeks according to clinical response . Therapy is generally initiated at the following doses: For patients up to 70 years of age: Oral, 250 mcg (0.25 mg) once a day . For patients 70 years of age and older or with impaired renal function: Oral, 125 mcg (0.125 mg) once a day . For patients with marked impaired renal function: Oral, 62.5 mcg (0.0625 mg) once a day . Atrial fibrillation, chronic-Doses should be titrated to the minimum dose that achieves the desired ventricular rate control without causing undesirable side effects .

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

Congestive heart failure-Beyond the immediate newborn period, children generally require proportionally larger doses than adults on the basis of body weight or body surface area . Children older than 10 years of age require adult dosages in proportion to their body weight . Some researchers have suggested that infants and young children tolerate slightly higher serum digoxin concentrations than do adults . For digitalization dosing of infants and children, see Digoxin Elixir USP or Digoxin Injection USP. The following daily maintenance doses are based on average patient response for children with normal renal function . Divided daily dosing is recommended for children up to 10 years of age: Maintenance- Children 2 to 5 years of age: Oral, 10 to 15 mcg (0.01 to 0.015 mg) per kg of body weight . Children 5 to 10 years of age: Oral, 7 to 10 mcg (0.007 to 0.01 mg) per kg of body weight . Children 10 years of age and older: Oral, 3 to 5 mcg (0.003 to 0.005 mg) per kg of body weight . 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

 

 

PREVIOUS

  

NEXT